Merck Stock Rating Reaffirmed Despite Cancer Treatment Optimism

Cantor Fitzgerald has reaffirmed its Neutral rating on Merck stock, setting a price target of $120.00. The firm notes that the upcoming ESMO event will be centered around the INTerpath-001 study, which was stopped early due to overwhelming efficacy in adjuvant melanoma.

Merk shares have seen significant gains, adding over $40 billion in market capitalization and reflecting a remarkable 91% return over the past year. The stock currently trades at $149.50, near its 52-week high of $156.92.

Cantor Fitzgerald states that meaningful credit is given to Merck's efforts beyond melanoma, with investors awaiting key data on the RFS hazard ratio, which is expected to be in the range of 0.6-0.65.